Hepatobiliary Surgery and Nutrition
Latest articles in this journal
Hepatobiliary Surgery and Nutrition; doi:10.21037/hbsn
Hepatobiliary Surgery and Nutrition, Volume 9, pp 247-249; doi:10.21037/hbsn.2019.11.35
Obesity represents a growing health problem in the United States and worldwide, with a prevalence that has doubled since 1980 (1). In the United States, 70% of adults and 37% of adolescents are overweight or obese. The chronic health implications of obesity make it a public health issue with significant economic ramifications. By promoting an altered whole-body physiology, obesity increases the risk for chronic diseases including diabetes, cardiovascular disease, and cancer (2).
Hepatobiliary Surgery and Nutrition, Volume 9, pp 269-270; doi:10.21037/hbsn.2020.03.18
Prof. John Chabot: working hard and asking important questions, but also keeping focused
Hepatobiliary Surgery and Nutrition, Volume 9, pp 267-268; doi:10.21037/hbsn.2020.01.08
Horrible hepatic portal venous gas
Hepatobiliary Surgery and Nutrition, Volume 9, pp 263-266; doi:10.21037/hbsn.2020.01.02
A primary hepatic neuroendocrine tumor disguised as hepatocellular carcinoma
Hepatobiliary Surgery and Nutrition, Volume 9, pp 260-262; doi:10.21037/hbsn.2019.12.08
Liver resections are more and more performed worldwide. While mortality for hepatic surgery is decreasing over the time, morbidity is still high and mostly affected by bile leak which remain the Achilles’ heel of this type of surgery. Indeed, still 3% to 33% of patients present bile leak in the post-operative period (1).
Hepatobiliary Surgery and Nutrition, Volume 9, pp 257-259; doi:10.21037/hbsn.2019.10.04
The highly effective direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection were well-received by both patients and physicians as sustained virological response (SVR) was associated with an improved overall survival in patients with stable liver disease, even in case of cirrhosis (1). Yet, at that time these results were derived from retrospective cohort studies with long-term follow-up after interferon-based therapy.
Hepatobiliary Surgery and Nutrition, Volume 9, pp 255-256; doi:10.21037/hbsn.2019.10.17
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the first cause of death in patients with cirrhosis. An increasing incidence worldwide and poor prognosis are reported despite the application of screening protocols and potentially radical therapies (1).
Hepatobiliary Surgery and Nutrition, Volume 9, pp 253-254; doi:10.21037/hbsn.2019.09.21
Lenvatinib is an oral molecular target agent that blocks vascular endothelial growth factor receptors 1–3, fibroblast growth factor receptors 1–4, platelet-derived growth factor receptor α, RET , and KIT . It is noninferior, but not statistically superior, to sorafenib with regard to overall survival, according to the findings of a phase 3 trial of lenvatinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma (HCC) (the REFLECT trial) (1). Nowadays, lenvatinib has been approved all over the world and has become the second front-line tyrosine kinase inhibitor in patients with advanced HCC. The recommendations for starting lenvatinib therapy for advanced HCC are different from those for other molecular target agents in patient with advanced HCC in that dose is based on body weight (≥60 kg: 12 mg once daily; <60 kg: 8 mg once daily). The aim of this article is to discuss the weight-based dosing of lenvatinib for advanced HCC.
Hepatobiliary Surgery and Nutrition, Volume 9, pp 250-252; doi:10.21037/hbsn.2020.03.16
Organ transplantation management in the midst of the COVID-19 outbreak: a synopsis